Evidence map›Paper›PMID 26506980›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2016

Mice with hepcidin-resistant ferroportin accumulate iron in the retina.

Milan Theurl, Delu Song, Esther Clark, Jacob Sterling, Steve Grieco, Sandro Altamura, Bruno Galy, Matthias Hentze, Martina U Muckenthaler, Joshua L Dunaief

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Milan Theurl*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Delu Song*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Esther Clark*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Jacob Sterling*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Steve Grieco*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Sandro Altamura*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Bruno Galy*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Matthias Hentze*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Martina U Muckenthaler*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany.
Joshua L Dunaief*F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria; Department of Psychiatry and Behavioral Sciences, and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA; Department of Pediatric Hematology, Oncology, and Immunology, University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany; and European Molecular Biology Laboratory, Heidelberg, Germany jdunaief@upenn.edu.
Penn Presbyterian Medical Center · USEuropean Molecular Biology Laboratory · DEUniversity Hospital Heidelberg · DEUniversity of Pennsylvania · USUniversity of Florida · US

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Qi N Cui · 1985 to 2026
$19.5M
Retinal Iron Transport in Health and DiseaseR01EY015240 · NEI · UNIVERSITY OF PENNSYLVANIA · PI JOSHUA L DUNAIEF · 2004 to 2026
$10.4M
NEI NIH HHS EY015240NEI NIH HHS P30 EY001583NEI NIH HHS R01 EY015240
6 · The paper itself

Abstract

Because ferroportin (Fpn) is the only known mammalian cellular iron exporter, understanding its localization and regulation within the retina would shed light on the direction of retinal iron flux. The hormone hepcidin may regulate retinal Fpn, as it triggers Fpn degradation in the gut. Immunofluorescence was used to label Fpn in retinas of mice with 4 different genotypes (wild type; Fpn C326S, a hepcidin-resistant Fpn; hepcidin knockout; and ceruloplasmin/hephaestin double knockout). No significant difference in Fpn levels was observed in these retinas. Fpn localized to the abluminal side of the outer plexiform vascular endothelial cells, Müller glia cells, and the basolateral side of the retinal pigment epithelium. Adeno-associated virus (AAV)-hepcidin was injected into the eyes of hepcidin knockout mice, while AAV-lacZ was injected into the contralateral eyes as a control. AAV-hepcidin injected eyes had increased ferritin immunolabeling in retinal vascular endothelial cells. Fpn C326S mice had systemic iron overload compared to wild type and had the fastest retinal iron accumulation of any hereditary model studied to date. The results suggest that physiologic hepcidin levels are insufficient to alter Fpn levels within the retinal pigment epithelium and Müller cells, but may limit iron transport into the retina from vascular endothelial cells.

Indexed as

Amino Acid SubstitutionAnimalsCation Transport ProteinsFerroportinHepcidinsIronMiceMice, KnockoutMutation, MissenseRetinal Pigment EpitheliumCation Transport ProteinsFerroportinHamp protein, mouseHepcidinsIronblood–brain barrieriron transportretinal pigment epitheliumvascular endothelium

Identifiers

PMID26506980
PMCPMC4714557
OpenAlexW1850330069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.